Better Coronavirus Stock: Gilead Sciences or Abbott Laboratories?
The coronavirus pandemic in the U.S. is now in its third wave. For stock investors, it's important to have at least one stock in your portfolio that can perform well amid the pandemic. Whether that's a business that does testing, is working on a vaccine, or provides a treatment option for COVID-19, a good coronavirus stock can help generate some returns for the foreseeable future, while other investments may struggle during these challenging times. It's also a great way to diversify your portfolio.
Two options are Gilead Sciences (NASDAQ: GILD) and Abbott Laboratories (NYSE: ABT). Gilead is well-known for its drug remdesivir, which can help treat patients with COVID-19, while Abbott has been a major player in testing for the virus. Let's take a close look at these two companies to see which one is the better coronavirus stock to buy today.
Shares of Gilead are down 10% year to date, well below the S&P 500, despite the 2% the stock gained in July following an analysis of positive trial results. That's also in spite of great news on Oct. 22, when the U.S. Food and Drug Administration (FDA) approved remdesivir for treating patients with COVID-19; if they're 12 or older and require hospitalization, they'll be eligible to use the drug.
Source Fool.com
